RESUMEN
PURPOSE OF REVIEW: H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal prognosis, so much so that the 2016 CNS WHO classification system created a specific category of "Diffuse Midline Glioma, H3K27M-mutant". Here we outline the latest pre-clinical data and ongoing current clinical trials that target H3K27M, as well as explore diagnosis and treatment monitoring by serial liquid biopsy. RECENT FINDINGS: Multiple epigenetic compounds have demonstrated efficacy and on-target effects in pre-clinical models. The imipridone ONC201 and the IDO1 inhibitor indoximod have demonstrated early clinical activity against H3K27M-mutant gliomas. Liquid biopsy of cerebrospinal fluid has shown promise for clinical use in H3K27M-mutant tumors for diagnosis and monitoring treatment response. While H3K27M has elicited a widespread platform of pre-clinical therapies with promise, much progress still needs to be made to improve outcomes for diffuse midline glioma patients. We present current treatment and monitoring techniques as well as novel approaches in identifying and targeting H3K27M-mutant gliomas.
Asunto(s)
Neoplasias Encefálicas , Glioma , Histona Demetilasas con Dominio de Jumonji/genética , Neoplasias de la Médula Espinal , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/genética , Líquido Cefalorraquídeo , Ensayos Clínicos como Asunto , Glioma/diagnóstico , Glioma/tratamiento farmacológico , Glioma/genética , Inhibidores de Histona Desacetilasas/uso terapéutico , Humanos , Inmunoterapia Adoptiva , Biopsia Líquida , Mutación , Pronóstico , Neoplasias de la Médula Espinal/diagnóstico , Neoplasias de la Médula Espinal/tratamiento farmacológico , Neoplasias de la Médula Espinal/genéticaRESUMEN
The original version of this review article unfortunately contained a mistake in the author group section.
RESUMEN
BACKGROUND: Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism behind tumor invasion. Previous reports demonstrate upregulation of the protein ID1 with H3K27M and ACVR1 mutations in DMG, but this has not been confirmed in human tumors or therapeutically targeted. METHODS: Whole exome, RNA, and ChIP-sequencing was performed on the ID1 locus in DMG tissue. Scratch-assay migration and transwell invasion assays of cultured cells were performed following shRNA-mediated ID1-knockdown. In vitro and in vivo genetic and pharmacologic [cannabidiol (CBD)] inhibition of ID1 on DMG tumor growth was assessed. Patient-reported CBD dosing information was collected. RESULTS: Increased ID1 expression in human DMG and in utero electroporation (IUE) murine tumors is associated with H3K27M mutation and brainstem location. ChIP-sequencing indicates ID1 regulatory regions are epigenetically active in human H3K27M-DMG tumors and prenatal pontine cells. Higher ID1-expressing astrocyte-like DMG cells share a transcriptional program with oligo/astrocyte-precursor cells (OAPCs) from the developing human brain and demonstrate upregulation of the migration regulatory protein SPARCL1. Genetic and pharmacologic (CBD) suppression of ID1 decreases tumor cell invasion/migration and tumor growth in H3.3/H3.1K27M PPK-IUE and human DIPGXIIIP* in vivo models of pHGG. The effect of CBD on cell proliferation appears to be non-ID1 mediated. Finally, we collected patient-reported CBD treatment data, finding that a clinical trial to standardize dosing may be beneficial. CONCLUSIONS: H3K27M-mediated re-activation of ID1 in DMG results in a SPARCL1+ migratory transcriptional program that is therapeutically targetable with CBD.
Asunto(s)
Neoplasias Encefálicas , Glioma , Animales , Humanos , Ratones , Encéfalo/patología , Neoplasias Encefálicas/genética , Proteínas de Unión al Calcio , Proteínas de la Matriz Extracelular/genética , Glioma/genética , Histonas/genética , Proteína 1 Inhibidora de la Diferenciación/genética , Mutación , Transducción de SeñalRESUMEN
Neurofibromatosis type 1 (NF1) is characterized by nerve tumors called neurofibromas, in which Schwann cells (SCs) show deregulated RAS signaling. NF1 is also implicated in regulation of cAMP. We identified the G-protein-coupled receptor (GPCR) P2ry14 in human neurofibromas, neurofibroma-derived SC precursors (SCPs), mature SCs, and mouse SCPs. Mouse Nf1-/- SCP self-renewal was reduced by genetic or pharmacological inhibition of P2ry14. In a mouse model of NF1, genetic deletion of P2ry14 rescued low cAMP signaling, increased mouse survival, delayed neurofibroma initiation, and improved SC Remak bundles. P2ry14 signals via Gi to increase intracellular cAMP, implicating P2ry14 as a key upstream regulator of cAMP. We found that elevation of cAMP by either blocking the degradation of cAMP or by using a P2ry14 inhibitor diminished NF1-/- SCP self-renewal in vitro and neurofibroma SC proliferation in in vivo. These studies identify P2ry14 as a critical regulator of SCP self-renewal, SC proliferation, and neurofibroma initiation.
Asunto(s)
AMP Cíclico/metabolismo , Neurofibroma , Neurofibromatosis 1 , Receptores Purinérgicos P2Y/metabolismo , Animales , Autorrenovación de las Células , Transformación Celular Neoplásica/metabolismo , Modelos Animales de Enfermedad , Ratones , Neurofibroma/genética , Neurofibroma/metabolismo , Neurofibroma/patología , Neurofibromatosis 1/genética , Neurofibromatosis 1/patología , Neurofibromina 1/genética , Neurofibromina 1/metabolismo , Células de Schwann/metabolismoRESUMEN
ATRX, a chromatin remodeler protein, is recurrently mutated in H3F3A-mutant pediatric glioblastoma (GBM) and isocitrate dehydrogenase (IDH)-mutant grade 2/3 adult glioma. Previous work has shown that ATRX-deficient GBM cells show enhanced sensitivity to irradiation, but the etiology remains unclear. We find that ATRX binds the regulatory elements of cell-cycle phase transition genes in GBM cells, and there is a marked reduction in Checkpoint Kinase 1 (CHEK1) expression with ATRX loss, leading to the early release of G2/M entry after irradiation. ATRX-deficient cells exhibit enhanced activation of master cell-cycle regulator ATM with irradiation. Addition of the ATM inhibitor AZD0156 doubles median survival in mice intracranially implanted with ATRX-deficient GBM cells, which is not seen in ATRX-wild-type controls. This study demonstrates that ATRX-deficient high-grade gliomas (HGGs) display Chk1-mediated dysregulation of cell-cycle phase transitions, which opens a window for therapies targeting this phenotype.
Asunto(s)
Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1)/metabolismo , Glioma/metabolismo , Proteína Nuclear Ligada al Cromosoma X/metabolismo , Animales , Neoplasias Encefálicas/metabolismo , Ciclo Celular/genética , Puntos de Control del Ciclo Celular/genética , Línea Celular Tumoral , Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1)/fisiología , Femenino , Histonas/metabolismo , Humanos , Isocitrato Deshidrogenasa/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Mutación , Recurrencia Local de Neoplasia/metabolismo , Cultivo Primario de Células , Proteína Nuclear Ligada al Cromosoma X/genéticaRESUMEN
BACKGROUND: Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. METHODS: We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D of the trial (n = 24) underwent serial lumbar puncture for cell-free tumor DNA (cf-tDNA) analysis and patients on all arms at the University of Michigan underwent serial plasma collection. We performed digital droplet polymerase chain reaction (ddPCR) analysis of cf-tDNA samples and compared variant allele fraction (VAF) to radiographic change (maximal 2D tumor area on MRI). RESULTS: Change in H3.3K27M VAF over time ("VAF delta") correlated with prolonged PFS in both CSF and plasma samples. Nonrecurrent patients that had a decrease in CSF VAF displayed a longer progression free survival (P = .0042). Decrease in plasma VAF displayed a similar trend (P = .085). VAF "spikes" (increase of at least 25%) preceded tumor progression in 8/16 cases (50%) in plasma and 5/11 cases (45.4%) in CSF. In individual cases, early reduction in H3K27M VAF predicted long-term clinical response (>1 year) to ONC201, and did not increase in cases of later-defined pseudo-progression. CONCLUSION: Our work demonstrates the feasibility and potential utility of serial cf-tDNA in both plasma and CSF of DMG patients to supplement radiographic monitoring. Patterns of change in H3K27M VAF over time demonstrate clinical utility in terms of predicting progression and sustained response and possible differentiation of pseudo-progression and pseudo-response.
Asunto(s)
Neoplasias Encefálicas , ADN Tumoral Circulante , Glioma , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/terapia , Niño , ADN Tumoral Circulante/genética , Glioma/diagnóstico , Glioma/genética , Glioma/terapia , Histonas/genética , Humanos , Imidazoles , Mutación , Piridinas , PirimidinasRESUMEN
PURPOSE: Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, Activin A receptor type I (ACVR1)-G328V (mACVR1), was developed for testing an immune-stimulatory gene therapy. EXPERIMENTAL DESIGN: We utilized the Sleeping Beauty transposase system to generate an endogenous mouse model of mACVR1 brainstem glioma. Histology was used to characterize and validate the model. We performed RNA-sequencing analysis on neurospheres harboring mACVR1. mACVR1 neurospheres were implanted into the pons of immune-competent mice to test the therapeutic efficacy and toxicity of immune-stimulatory gene therapy using adenoviruses expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 neurospheres expressing the surrogate tumor antigen ovalbumin were generated to investigate whether TK/Flt3L treatment induces the recruitment of tumor antigen-specific T cells. RESULTS: Histologic analysis of mACVR1 tumors indicates that they are localized in the brainstem and have increased downstream signaling of bone morphogenetic pathway as demonstrated by increased phospho-smad1/5 and Id1 levels. Transcriptome analysis of mACVR1 neurosphere identified an increase in the TGFß signaling pathway and the regulation of cell differentiation. Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas resulted in antitumor immunity, recruitment of antitumor-specific T cells, and increased median survival (MS). CONCLUSIONS: This study provides insights into the phenotype and function of the tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. Immune-stimulatory gene therapy targeting the hosts' antitumor immune response inhibits tumor progression and increases MS of mice bearing mACVR1 tumors.
Asunto(s)
Neoplasias del Tronco Encefálico/terapia , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Glioma/terapia , Inmunoterapia/métodos , Receptores de Activinas Tipo I/genética , Animales , Neoplasias del Tronco Encefálico/genética , Neoplasias del Tronco Encefálico/inmunología , Neoplasias del Tronco Encefálico/patología , Modelos Animales de Enfermedad , Femenino , Vectores Genéticos/genética , Glioma/genética , Glioma/inmunología , Glioma/patología , Humanos , Masculino , Proteínas de la Membrana/genética , Ratones , Ratones Transgénicos , Mutación , Puente/patología , Cultivo Primario de Células , RNA-Seq , Transducción de Señal/genética , Transducción de Señal/inmunología , Esferoides Celulares , Timidina Quinasa/genética , Factor de Crecimiento Transformador beta/metabolismo , Células Tumorales Cultivadas/trasplante , Microambiente Tumoral/genética , Microambiente Tumoral/inmunologíaRESUMEN
To analyse the anatomical and functional outcomes of Boston type II keratoprosthesis at a tertiary eye care centre in South India. Retrospective chart review of 10 patients operated with Boston keratoprosthesis Type 2 between Feb 2013 and June 2017 were analysed. Outcome measures analysed included, visual outcome, device retention and postoperative complications. The most common indication for surgery was SJS in 80% (8 of 10 eyes). Mean follow-up duration was 2.75 years (0.5-5 years, SDâ¯-â¯1.71, median 32 months) Postoperative visual acuity improved to better than 20/200 in 7 eyes and better than 20/30 in 6 eyes with device retention in 9 eyes at last follow-up. Pre-existing glaucoma was noted in 1 eye. RPM was noted in 1 eye, retinal detachment in 1 eye, endophthalmitis in 1 eye and sterile melt requiring kpro replacement in 1 eye. No progression or development of glaucoma was noted postoperatively in any eye . Boston type 2 keratoprosthesis is a viable option to restore vision in patients with end stage ocular surface disorders. Though the procedure can be associated with complications, early as well as late, our midterm outcome appears to be encouraging.